Sté Tunisienne des Maladies Respiratoires et d'Allergologie
Cercle des Bureaux - Appartement B 5-3 . 1082 Centre urbain Nord Tunis
![[Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent](/media/k2/items/cache/1659cc75227694996edfedee430cb4a4_L.jpg)
[Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
New data show treatment with Lilly’s neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent – Lilly Commentary: Lilly antibody combo therapy cuts risk of COVID-19 deaths – Reuters Commentary on Twitter 1st Phase 3 trial results on #SARSCoV2 monoclonal antibody combination with very positive […]
The post [Press release – not published yet] Neutralizing antibodies bamlanivimab and etesevimab together reduced risk of COVID-19 hospitalizations and death by 70 percent appeared first on Links Medicus.
-
Taille de police
Réduire la taille de la police
Augmenter la taille de police
About Author
Dernier de Zouhair Souissi
- RCT: ICS-Formoterol and ICS-SABA Reduce Severe Asthma Exacerbations Compared With SABA Alone
- ATS Guideline: Evaluation and Management of Obesity Hypoventilation Syndrome
- RCT: Telehealth-Delivered Early Palliative Care Equivalent to In-Person Care in Advanced Lung Cancer
- Summary: Perioperative Management of Patients Taking Direct Oral Anticoagulants
- Summary: Community-Acquired Pneumonia
Laissez un commentaire
Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.